

Presenting Company Profiles

 **biofuture**TM

Reimagine the future of healthcare

October 28–30, 2024
New York City



WHERE GLOBAL BIOTECH LEADERS CONNECT

Upcoming DEMY COLTON Events

 virtualsalons

Throughout
the year

**BIOTECH
SHOWCASE™**

JAN 13-15

**TECHBIO
SHOWCASE**

JAN 13-15

**SEED
SHOWCASE**

JAN 13-15

 BIOTECH
ceosummit™
EUROPE

TBA

 BIOTECH
ceosummit™
USA

TBA

 biofuture™

TBA

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

Table of Contents

BioFuture Presenting Company Profiles..... 1

BioFuture Categorical Listings 21

Seed Showcase Presenting Company Profiles 31

Seed Showcase Categorical Listings..... 41



TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

BioFuture Presenting Company Profiles

TechBio Companies

AiM Medical Robotics
AtlasXomics Inc.
Excelsior Sciences, Inc
Glucotrack Inc.
Hervolution Therapeutics
iBio, Inc.
Ideal Medical Technologies Inc.
Kaleidoscope.bio
Nusano

Pictura Bio Ltd
Polaris Quantum Biotech, LTD
Portrai
Rx Bandz
Talus Bio
XCMR Inc.

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

Aegle Therapeutics Corporation

Categorical Listings: Cell Therapy, Inflammation, Orphan-Rare Disease

Location: Woburn, Massachusetts United States

Year Established: 2019 **Website:** www.aegletherapeutics.com

Corporate Partners: Currently none.

Funds Raised: INP

Presenter: Shelley Hartman, CEO



AiM Medical Robotics

(TechBio)

Categorical Listings: Drug Delivery, Neurology, Oncology

Location: Worcester, Massachusetts United States

Year Established: 2018 **Website:** www.aimmedicalrobotics.com

Corporate Partners: Active discussion/negotiation for co-development with: Medtronic, Siemens, Boston Scientific, and Novo Nordisk.

Funds Raised: \$6M to date, company supported by additional \$15M in NIH-funded R&D.

Presenter: Gregory Fischer, PhD, MSE, Founder & CEO

AtlasXomics Inc.

(TechBio)

Categorical Listings: Bioinformatics, Drug Discovery, Epigenetics

Location: New Haven, Connecticut United States

Year Established: 2020 **Website:** www.atlasxomics.com

Corporate Partners: Partnerships with EpiCypher, the leading provider of reagents for epigenetic assays and LatchBio, a cloud-based platform to analyze data for biological R&D. Part of NVIDIA Inception, the company's accelerator for startups.

Funds Raised: Raised \$14.5M through Seed-1, Seed-2, and Series A Preferred. Also received \$3.1M in SBIR grants.

Presenter: Kenneth (Ken) Wang, MS, MBA, CEO

AvantGuard Inc

Categorical Listings: Dermatology, Infectious Disease, Platform Technology

Location: Ithaca, New York United States

Year Established: 2018 **Website:** www.avantguardinc.com

Corporate Partners: The company does not have corporate partners yet.

Funds Raised: \$8M in grant funding from the NIH, NSF and others and \$4M in equity.

Presenter: Ted Eveleth, CEO

TOC

BF
profilesBF
CategoricalSEED
profilesSEED
Categorical

AyuVis Research, Inc.

Categorical Listings: Immunology, Orphan-Rare Disease, Platform Technology

Location: Fort Worth, Texas United States

Year Established: 2014 **Website:** www.ayuviz.com

Corporate Partners: In discussions with corporate partners for lead program and other pipeline programs.

Funds Raised: Total to date is \$10.6M; \$4.9M in non-dilutive NIH grants and \$5.7M in Seed funding.

Presenter: Mariam Morris, CPA, MS, CFO

Biotech Therapeutics, LLC

Categorical Listings: Cell Therapy, CNS-Neurological, Regenerative Medicine

Location: Estero, Florida United States

Year Established: 2022 **Website:** www.biotechtherapeutics.us

Corporate Partners: Confidential.

Funds Raised: Not including information about funding to date in the handbook.

Presenter: John Barchilon, MD, CEO

BioXtek LLC

Categorical Listings: Cardiovascular, Fibrosis, Inflammation

Location: Pompano Beach, Florida United States

Year Established: 2022 **Website:** bioxtek.com

Corporate Partners: The company does not have any corporate partners at this time.

Funds Raised: Seed round \$2M.

Presenter: Bruce Werber, DPM, MSc, CEO



BlinkLab Limited (ASX:BB1)

Categorical Listings: Diagnostics, Machine Learning, Neurology

Location: Sydney, Australia

Year Established: 2021 **Website:** www.blinklab.org

Corporate Partners: The company's product was developed in partnership with Princeton University and is being actively tested by top research partners including Baylor College of Medicine, Columbia University, Scanner Consortium, etc.

Funds Raised: AUD\$9.6M to date, including AUD\$7M in ASX IPO in 2024.

Presenter: Henk-Jan Boele, MD, PhD, CEO

Bostal LLC

Categorical Listings: Cardiovascular, CNS-Neurological, Psychiatric

Location: Edison, New Jersey United States

Year Established: 2004 **Website:** www.bostaldrug.com/en

Corporate Partners: INP

Funds Raised: INP

Presenter: Ron Liu, PhD, MBA, CEO

Boston Immune Technologies and Therapeutics, Inc.

Categorical Listings: Antibodies, Autoimmune, Immuno-oncology

Location: Winchester, Massachusetts United States

Year Established: 2015 **Website:** www.bostonimmunetech.com

Corporate Partners: BITT has an undisclosed pharma partner for its CD40 program.

Funds Raised: \$20M in venture and non-dilutive funding including a \$10M 2021 A Round.

Presenter: Russell LaMontagne, MS, CEO



CellFE Inc.

Categorical Listings: Biomufacturing, Cell Therapy, Immuno-oncology

Location: Alameda, California, United States

Year Established: 2020 **Website:** www.cellfebiotech.com

Corporate Partners: Large pharma, translational centers, integration partners.

Funds Raised: \$35M to date.

Presenter: Alla Zamarayeva, PhD, CEO

Chimeron Bio

Categorical Listings: Immuno-oncology, Oncology Combination Therapy, Platform Technology

Location: Philadelphia, Pennsylvania United States

Year Established: 2022 **Website:** www.chimeron.com

Corporate Partners: No corporate partnerships but Chimeron does have an on-going collaboration with several academic parties.

Funds Raised: INP

Presenter: Kevin Heyeck, CEO

Cytonus Therapeutics

Categorical Listings: Biomanufacturing, Cell Therapy, Drug Delivery

Location: Carlsbad, California United States

Year Established: 2018 **Website:** www.cytonus.com

Corporate Partners: Cytonus' product HEstem is being developed with Medinno Inc.

Funds Raised: \$19M in total, with \$6M in grant funding.

Presenter: Remo Moomiaie-Qajar, MD, CEO



Excelsior Sciences, Inc

(TechBio)

Categorical Listings: Big Data, Drug Discovery, Machine Learning

Location: New York, New York United States

Year Established: 2024 **Website:** not yet available

Corporate Partners: The company is currently in discussions regarding an initial partnership.

Funds Raised: \$20M Series A to date; \$30M Series A extension anticipated by mid-2025. \$25M grant from Empire State Development.

Presenter: Michael (Mike) Foley, PhD, CEO

FlyteHealth

Categorical Listings: Cardiovascular, Endocrine-Metabolic, Personalized Medicine

Location: New Canaan, Connecticut United States

Year Established: 2018 **Website:** www.flytehealth.com

Corporate Partners: FlyteHealth partners with carriers, PBMs, consultants and resellers to provide its service to group employers, government entities, and labor unions.

Funds Raised: Round A

Presenter: Gabe Castaneda, MBA, Chief Revenue Officer

Glucotrack Inc. (NASDAQ:GCTK) (TechBio)

Categorical Listings: Diagnostics, Endocrine-Metabolic, Neuropathy/Pain

Location: Rutherford, New Jersey United States

Year Established: 2001 **Website:** www.glucotrack.com

Corporate Partners: There are ongoing discussions with potential strategic partners.

Funds Raised: Approximately \$80M to date, with a clean cap table.

Presenter: Paul Vincent Goode, PhD, CEO



Helex, Inc.

Categorical Listings: CRISPR, Platform Technology, Renal

Location: New York, New York United States

Year Established: 2021 **Website:** www.helex.bio

Corporate Partners: No active partnerships currently. Open for biopharma partnerships for later-stage development of the lead asset and other indications.

Funds Raised: \$3M in pre-Seed financing led by SOSV. Non-dilutive awards from NIH, Deerfield Management, and Cartier Women’s Initiative.

Presenter: Poulami Chaudhuri, PhD, MSc, CEO & Co-Founder

Helfie AI

Categorical Listings: Artificial Intelligence (AI), Natural language processing (NLP)/ Large language models (LLM), Personalized Medicine

Location: Melbourne, Australia

Year Established: 2021 **Website:** www.helfie.ai

Corporate Partners: Helfie AI is the sole developer of its products, though several of its products are also available on Microsoft’s Azure Marketplace, with direct licensing options for Microsoft Enterprise customers.

Funds Raised: INP

Presenter: George Tomeski, CEO

Hervolution Therapeutics

(TechBio)

Categorical Listings: CNS-Neurological, Immuno-oncology, Longevity/Healthspan/ Diseases of Aging

Location: København N, Denmark

Year Established: 2011 **Website:** hervolutiontx.com

Corporate Partners: INP

Funds Raised: \$20M total. First close of \$10M of Series A in Q2 2024. Now raising for 2nd close.

Presenter: Robert Coleman, PhD, MBA, CEO

TOC

BF profiles

BF Categorical

SEED profiles

SEED Categorical

Iaso Biotherapeutics

Categorical Listings: Antibodies, Autoimmune, Cell Therapy

Location: Shanghai, China

Year Established: 2017 **Website:** www.iasobio.com

Corporate Partners: Licensed BCMA CAR construct to Sana Biotechnology; Licensed CD19 binder to Cabaletta Bio for autoimmune CART therapy; Entered into co-development agreements with Umoja Biopharma on in vivo CART.

Funds Raised: In aggregate over \$200M since inception.

Presenter: Alan Fu, PhD, CFO

iBio, Inc. (NYSE:IBIO)

(TechBio)

Categorical Listings: Antibodies, Artificial Intelligence (AI), Drug Discovery

Location: San Diego, California United States

Year Established: 2008 **Website:** ibioinc.com

Corporate Partners: iBio and partner AstralBio are discovering and developing antibodies for cardiometabolic conditions. Their lead program focuses on the transforming growth factor beta (TGFb) superfamily for treating muscle wasting and obesity.

Funds Raised: INP

Presenter: Martin Brenner, DVM, PhD, CEO & CSO

Ideal Medical Technologies Inc. (TechBio)

Categorical Listings: Drug Delivery, Endocrine-Metabolic, Machine Learning

Location: Asheville, North Carolina United States

Year Established: 2014 **Website:** www.idealmedtech.com

Corporate Partners: The company's clinical studies are being supported by Dexcom.

Funds Raised: \$3M to date in Seed round funding.

Presenter: Leon DeJournett, MD, CEO

TOC

BF
profilesBF
CategoricalSEED
profilesSEED
Categorical

Illudent Therapeutics

Categorical Listings: Drug Discovery, Oncology, Personalized Medicine

Location: San Diego, California, United States

Year Established: 2020 **Website:** illudent.com

Corporate Partners: The company is actively seeking corporate partners for ITX-121, as well as for ITX-122, its c-MYC-specific compound in development.

Funds Raised: \$1.2M Seed financing October 2023.

Presenter: Mark Benedyk, PhD, Senior Advisor

Immunis, Inc.

Categorical Listings: Endocrine-Metabolic, Musculoskeletal, Regenerative Medicine

Location: Irvine, California United States

Year Established: 2019 **Website:** www.immunisbiomedical.com

Corporate Partners: Immunis entered a licensing partnership with Toray Pharma to develop their TRK-820 asset to treat sarcopenia.

Funds Raised: \$13M year-to-date including \$10M in Series A round (2022).

Raising \$20M in Series A-1 round, expected close in 3Q2024.

Presenter: Hans Keirstead, PhD, Chairman of the Board

Indaptus Therapeutics, Inc. (NASDAQ:INDP)

Categorical Listings: Immunology, Immuno-oncology, Oncology Combination Therapy

Location: New York, New York United States

Year Established: 2021 **Website:** www.indaptusrx.com

Corporate Partners: The company has not partnered to date.

Funds Raised: \$30M in August 2021. \$3M in August 2024.

Presenter: Jeffrey Meckler, MS, CEO



Kadence Bio

Categorical Listings: CNS-Neurological, Psychiatric

Location: Kent, United Kingdom

Year Established: 2021 **Website:** www.kadencebio.com

Corporate Partners: INP

Funds Raised: \$12.3M total: \$10M Seed and convertible notes in 2021-2022, and \$2.3M pre-Series A convertible notes (current round).

Presenter: Ryan Protzko, PhD, President

Kaleidoscope.bio

(TechBio)

Categorical Listings: Drug Discovery, Platform Technology, Research Tools

Location: New York, New York United States

Year Established: 2021 **Website:** www.kaleidoscope.bio

Corporate Partners: INP

Funds Raised: \$6M

Presenter: Bogdan Knezevic, PhD, Co-Founder & CEO

LIFT BioSciences

Categorical Listings: Cell Therapy, Immuno-oncology, Platform Technology

Location: London, United Kingdom

Year Established: 2016 **Website:** www.liftbiosciences.com

Corporate Partners: Lead asset and LIFT's IMAN neutrophil platform are wholly owned by LIFT.

Funds Raised: INP

Presenter: Antonin (Tony) de Fougères, PhD, Chairman



Lisata Therapeutics, Inc. (NASDAQ:LSTA)

Categorical Listings: Drug Delivery, Oncology, Oncology Combination Therapy

Location: Basking Ridge, New Jersey United States

Year Established: 1980 **Website:** www.lisata.com

Corporate Partners: Platform technology "validated" by existing partnerships with potential for many others.

Funds Raised: \$43.3M in cash & investments as of 3/31/2024 projected to fund the company's ongoing and planned clinical trials to data.

Presenter: David J. Mazzo, PhD, President & CEO

Molecular You

Categorical Listings: Bioinformatics, Longevity/Healthspan/Diseases of Aging, Personalized Medicine

Location: Vancouver, Washington United States

Year Established: 2014 **Website:** www.molecularyou.com

Corporate Partners: The company's laboratory work is processed by HealthQuest Esoterics in California. This partner also acts as a distributor line of business.

Funds Raised: \$17.5M to date, \$5M of which is non-dilutive government grants.

Presenter: Jim Kean, MBA, CEO

NUP-CTx Inc.

Categorical Listings: Oncology Combination Therapy

Location: Cape Coral, Florida United States

Year Established: 2024 **Website:** www.nupctx.com

Corporate Partners: The company is a spin-off from a university.

Funds Raised: Private money from the founder.

Presenter: Kai Blau, PhD, Business Director



Nusano

(TechBio)

Categorical Listings: Oncology, Platform Technology, Radiopharmaceuticals

Location: Valencia, California United States

Year Established: 2015 **Website:** www.nusano.com

Corporate Partners: Nusano has a supply agreement in place and a CDMO collaboration relationship with PharmaLogic.

Funds Raised: INP

Presenter: Rohan Jain, MBA, Chief Commercial Officer

Opus Genetics (NASDAQ:IRD)

Categorical Listings: Gene Therapy, Ophthalmic

Location: Farmington Hills, Michigan, United States

Year Established: 2017 **Website:** opusgtx.com

Corporate Partners: Opus' phentolamine ophthalmic solution product is partnered for commercialization.

Funds Raised: Last public raise was in 2022.

Presenter: George Magrath, MD, MBA, CEO

Origami Therapeutics, Inc.

Categorical Listings: CNS-Neurological, Longevity/Healthspan/Diseases of Aging, Orphan-Rare Disease

Location: San Diego, California United States

Year Established: 2015 **Website:** origamitherapeutics.com

Corporate Partners: No current partners.

Funds Raised: \$7M to date, including \$5.5M from convertible notes (SAFEs) and \$1.5M in non-dilutive funding.

Presenter: Beth J. Hoffman, PhD, CEO

TOC

BF
profilesBF
CategoricalSEED
profilesSEED
Categorical

Osmol Therapeutics, Inc.

Categorical Listings: Neurology, Neuropathy/Pain, Oncology

Location: New Haven, Connecticut United States

Year Established: 2017 **Website:** www.osmoltherapeutics.com

Corporate Partners: Have identified pharma company interested in Osmol's product. Discussions are ongoing.

Funds Raised: \$8.8M in private capital to date.

Presenter: Bob Linke, MBA, President & CEO

OYE Therapeutics, Inc.

Categorical Listings: CNS-Neurological, Platform Technology, Pulmonary

Location: Crown Point, Indiana United States

Year Established: 2019 **Website:** www.ogetherapeutics.com

Corporate Partners: Prevail Partners, US Dept. of Defense

Funds Raised: \$2.5M SAFEs. \$7M Non-dilutive. \$5M convertible note lead by strategic partner/investor with \$2M closed to date.

Presenter: Brett Dines, RPh, MBA, CEO & Founder

Pictura Bio Ltd

(TechBio)

Categorical Listings: Diagnostics, Infectious Disease, Machine Learning

Location: Oxford, United Kingdom

Year Established: 2021 **Website:** www.pictura.bio

Corporate Partners: The company works with private and public health systems.

Funds Raised: \$8M to date including \$2M non-dilutive.

Presenter: Alex Batchelor, CEO

TOC

BF profiles

BF Categorical

SEED profiles

SEED Categorical

Polaris Quantum Biotech, LTD

(TechBio)

Categorical Listings: Drug Discovery, Platform Technology, Quantum Computing

Location: Durham, North Carolina United States

Year Established: 2020 **Website:** www.polarisqb.com

Corporate Partners: Under NDA.

Funds Raised: Under NDA.

Presenter: Shahar Keinan, PhD, CEO

Portrai

(TechBio)

Categorical Listings: Antibodies, Bioinformatics, Radiopharmaceuticals

Location: Seoul, South Korea

Year Established: 2021 **Website:** portrai.io/en

Corporate Partners: INP

Funds Raised: INP

Presenter: Hyung-Jun Im, MD, PhD, CSO

Port Therapeutics

Categorical Listings: Cell Therapy, Gene Therapy, Oncology

Location: Los Angeles, California, United States

Year Established: 2021 **Website:** porttherapeutics.com

Corporate Partners: The company is in active discussion with prospective partners.

Funds Raised: \$8.5M priced Seed round from institutional investors in 2022.

Presenter: João Siffert, MD, MBA, CEO



Rx Bandz

(TechBio)

Categorical Listings: Drug Delivery, Drug Discovery, Platform Technology

Location: Fairfield, New Jersey United States

Year Established: 2016 **Website:** www.rxbandz.com

Corporate Partners: The company has a strategic partnership with award-winning precision manufacturer Weiss-Aug. The DoD has awarded RxBandz over 13 military contracts with rights to sole-source and eligibility for follow-on matching funds.

Funds Raised: \$11M in dilutive and non-dilutive funds.

Presenter: Jessica Walsh, CEO & Founder

Talus Bio

(TechBio)

Categorical Listings: Artificial Intelligence (AI), Drug Discovery, Proteomics

Location: Seattle, Washington United States

Year Established: 2020 **Website:** www.talus.bio

Corporate Partners: The pipeline is fully-owned by Talus Bio.

Funds Raised: \$27M to date with nearly \$8M in non-dilute grant funding for technology development.

Presenter: Alex Federation, PhD, CEO & Co-Founder

Thrive Bioscience, Inc.

Categorical Listings: Drug Discovery, Machine Learning, Regenerative Medicine

Location: Beverly, Massachusetts United States

Year Established: 2014 **Website:** www.thrivebio.com

Corporate Partners: Thrive has collaborations with a large pharma and with six leading hospitals and medical schools in fields of stem cell research, tissue culture, regenerative medicine, oncology, and infectious disease research.

Funds Raised: \$42M from family offices, Angel groups, and funds and currently raising a \$25M Series B.

Presenter: Thomas (Tom) Forest Farb-Horch, CEO & President



Tivic Health Systems, Inc. (NASDAQ:TIVC)

Categorical Listings: Autoimmune, Neurology, Other

Location: Fremont, California United States

Year Established: 2016 **Website:** tivichealth.com

Corporate Partners: Tivic's commercial product tested at Stanford Medical. Distributed by McKesson, Cardinal, Cencora, Amazon and direct. VNS being done at The Feinstein Institutes for Medical Research-Northwell Health.

Funds Raised: INP

Presenter: Jennifer Ernst, CEO

Valley Fever Solutions, Inc.

Categorical Listings: Artificial Intelligence (AI), Infectious Disease, Orphan-Rare Disease

Location: Tucson, Arizona United States

Year Established: 2007 **Website:** www.valleyfeversolutions.com

Corporate Partners: The company has benefitted from \$7M direct and \$2.5M indirect NIH support. It plans to qualify for BARDA support to take it to commercial introduction.

Funds Raised: \$7M direct and \$2.5M indirect NIH support, \$1M from foundations and founders.

Presenter: David Larwood, PhD, MBA, CEO

VSP PharmTech

Categorical Listings: Oncology, Oncology Combination Therapy

Location: Nowon-gu, Seoul, South Korea

Year Established: 2018 **Website:** www.vsp pharmtech.com

Corporate Partners: Actively seeking partnership with multinational pharmaceutical companies which are interested in radiotherapy areas such as radioligand therapy.

Funds Raised: \$13M in total after the Series B round in 2023.

Presenter: Hoyun Nam, Director



XCMR Inc.

(TechBio)

Categorical Listings: Infectious Disease, Pulmonary

Location: Narberth, Pennsylvania United States

Year Established: 2020 **Website:** www.xcmr.co

Corporate Partners: Funding partners include Department of Defense (DoD), Department of Energy (DoE), EPA following. Research institution partners include: University of Colorado, Boulder, Purdue, Columbia, NC State.

Funds Raised: \$1.7M SAFE to date in addition to \$2.7M in DoD, DoE and EPA R&D contracts.

Presenter: Richard Rasansky, CEO

XYone Therapeutics Inc

Categorical Listings: Antibodies, Oncology

Location: Canton, Massachusetts, United States

Year Established: 2021 **Website:** www.xyonetx.com

Corporate Partners: Antibodies are out licensed to Poseida Therapeutics for use in CAR-T: Poseida received \$50M for just the first look rights from Astellas.

Funds Raised: The company raised \$7.5M in their first round. Now raising \$48M.

Presenter: Anshu Goyal, CEO

Ziphius

Categorical Listings: Gene Therapy, Infectious Disease, Platform Technology

Location: New York, New York United States

Year Established: 2019 **Website:** www.ziphius.org

Corporate Partners: The company is not co-developing its product; however, is open to licensing opportunities with a major pharmaceutical partner in the future.

Funds Raised: Seed 2020: €3M. Series A 2021: €29.3M. Milestone achievement 2023: €5M.

Presenter: Hanne Noyen, Scientific Liaison Manager



TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

BioFuture Categorical Listings

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

Antibodies

Boston Immune Technologies and Therapeutics, Inc.
 Iaso Biotherapeutics
 iBio, Inc.
 Portrai
 XYone Therapeutics Inc

Artificial Intelligence (AI)

Helfie AI
 iBio, Inc.
 Talus Bio
 Valley Fever Solutions, Inc.

Autoimmune

Boston Immune Technologies and Therapeutics, Inc.
 Iaso Biotherapeutics
 Tivic Health Systems, Inc.

Big Data

Excelsior Sciences, Inc

Bioinformatics

AtlasXomics Inc.
 Molecular You
 Portrai

Biomanufacturing

CellFE Inc.
 Cytonus Therapeutics



Cardiovascular

BioXtek LLC

Bostal LLC

FlyteHealth

Cell Therapy

Aegle Therapeutics Corporation

Biotech Therapeutics, LLC

CellFE Inc.

Cytonus Therapeutics

Iaso Biotherapeutics

LIFT BioSciences

Port Therapeutics

CNS-Neurological

Biotech Therapeutics, LLC

Bostal LLC

Hervolution Therapeutics

Kadence Bio

Origami Therapeutics, Inc.

OYE Therapeutics, Inc.

CRISPR

Helex, Inc.

Dermatology

AvantiGuard Inc

TOC

BF

profiles

BF

Categorical

SEED

profiles

SEED

Categorical

Diagnostics

BlinkLab Limited
 GlucoTrack Inc.
 Pictura Bio Ltd

Drug Delivery

AiM Medical Robotics
 Cytonus Therapeutics
 Ideal Medical Technologies Inc.
 Lisata Therapeutics, Inc.
 Rx Bandz

Drug Discovery

AtlasXomics Inc.
 Excelsior Sciences, Inc
 iBio, Inc.
 Illudent Therapeutics
 Kaleidoscope.bio
 Polaris Quantum Biotech, LTD
 Rx Bandz
 Talus Bio
 Thrive Bioscience, Inc.

Endocrine-Metabolic

FlyteHealth
 GlucoTrack Inc.
 Ideal Medical Technologies Inc.
 Immunis, Inc.

Epigenetics

AtlasXomics Inc.



Fibrosis

BioXtek LLC

Gene Therapy

Opus Genetics

Port Therapeutics

Ziphius

Immunology

AyuVis Research, Inc.

Indaptus Therapeutics, Inc.

Immuno-oncology

Boston Immune Technologies and Therapeutics, Inc.

CellFE Inc.

Chimeron Bio

Hervolution Therapeutics

Indaptus Therapeutics, Inc.

LIFT BioSciences

Infectious Disease

AvantGuard Inc

Pictura Bio Ltd

Valley Fever Solutions, Inc.

XCMR Inc.

Ziphius

Inflammation

Aegle Therapeutics Corporation

BioXtek LLC

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

Longevity/Healthspan/Diseases of Aging

Hervolution Therapeutics
 Molecular You
 Origami Therapeutics, Inc.

Machine Learning

BlinkLab Limited
 Excelsior Sciences, Inc
 Ideal Medical Technologies Inc.
 Pictura Bio Ltd
 Thrive Bioscience, Inc.

Musculoskeletal

Immunis, Inc.

Natural language processing (NLP)/Large language models (LLM)

Helfie AI

Neurology

AiM Medical Robotics
 BlinkLab Limited
 Osmol Therapeutics, Inc.
 Tivic Health Systems, Inc.

Neuropathy/Pain

Glucotrack Inc.
 Osmol Therapeutics, Inc.



Oncology

AiM Medical Robotics

Illudent Therapeutics

Lisata Therapeutics, Inc.

Nusano

Osmol Therapeutics, Inc.

Port Therapeutics

VSPHarmTech

XYone Therapeutics Inc

TOC

BF

profiles

BF

Categorical

SEED

profiles

SEED

Categorical

Oncology Combination Therapy

Chimeron Bio

Indaptus Therapeutics, Inc.

Lisata Therapeutics, Inc.

NUP-CTx Inc.

VSPHarmTech

Ophthalmic

Opus Genetics

Orphan-Rare Disease

Aegle Therapeutics Corporation

AyuVis Research, Inc.

Origami Therapeutics, Inc.

Valley Fever Solutions, Inc.

Other

Tivic Health Systems, Inc.

Personalized Medicine

- FlyteHealth
- Helfie AI
- Illudent Therapeutics
- Molecular You

Platform Technology

- AvantGuard Inc
- AyuVis Research, Inc.
- Chimeron Bio
- Helex, Inc.
- Kaleidoscope.bio
- LIFT BioSciences
- Nusano
- OYE Therapeutics, Inc.
- Polaris Quantum Biotech, LTD
- Rx Bandz
- Ziphius

Proteomics

- Talus Bio

Psychiatric

- Bostal LLC
- Kadence Bio

Pulmonary

- OYE Therapeutics, Inc.
- XCMR Inc.



Quantum Computing

Polaris Quantum Biotech, LTD

Radiopharmaceuticals

Nusano

Portrai

Regenerative Medicine

Biotech Therapeutics, LLC

Immunis, Inc.

Thrive Bioscience, Inc.

Renal

Helex, Inc.

Research Tools

Kaleidoscope.bio

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

Seed Showcase Presenting Company Profiles

TechBio Companies

BioCurie
Lyric Bio, Inc.
OncoRx Insights, Inc.
Oqory, Inc.
ReSync Bio, Inc

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

BioCurie

(TechBio)

Categorical Listings: Artificial Intelligence (AI), Biomanufacturing, Gene Therapy

Location: Wilmington, Delaware, United States

Year Established: 2021 **Website:** www.biocurie.com

Corporate Partners: Multi-national major biopharmaceutical company (confidential).

Funds Raised: INP

Presenter: Irene Rombel, PhD, MBA, CEO, President & Co-Founder



CARLA Biotherapeutics

Categorical Listings: Cell Therapy, Oncology, Personalized Medicine

Location: Besançon, Bourgogne-Franche-Comté, France

Year Established: 2023 **Website:** www.carla-biotherapeutics.com

Corporate Partners: None

Funds Raised: Total grant money <\$2M.

Presenter: Zaki Sellam, MBA, MSc, Co-Founder & President

ImBiome Inc.

Categorical Listings: Drug Delivery, Microbiome, Platform Technology

Location: Albany, New York, United States

Year Established: 2023 **Website:** www.imbiome.com

Corporate Partners: Technology transfer partner is confidential; in summary - \$25M invested in products, 15 million patients dosed, 400 million doses manufactured in another jurisdiction.

Funds Raised: Closing 1st tranche (~\$1M) of a \$2M pre-Seed round. Planning to raise ~\$10M in H1 2025.

Presenter: Peter Michels, PhD, Co-Founder, CEO & CSO

Invenis Biotherapies

Categorical Listings: CNS-Neurological, Orphan-Rare Disease, Regenerative Medicine

Location: Loos, France

Year Established: 2021 **Website:** www.invenis-biotherapies.com

Corporate Partners: Etablissement Français du Sang for platelet supply. Bio Elpida, a CDMO, for the development of the product. Medtronic for the supply of the infusion pump (under discussion).

Funds Raised: €4.1M in grants, payment of which is conditional on raising funds from private investors. €50K in private equity.

Presenter: Boris Molle, PhD, CEO



Kaida BioPharma

Categorical Listings: Other

Location: Fort Lauderdale, Florida United States

Year Established: 2022 **Website:** www.kaida-biopharma.com

Corporate Partners: In process with SRA with MD Anderson.

Funds Raised: \$1M

Presenter: Craig Pierson, Chairman

Kalm Therapeutics

Categorical Listings: Dermatology, Immunology, Microbiome

Location: Huntsville, Alabama United States

Year Established: 2024 **Website:** www.kalmtherapeutics.com

Corporate Partners: Kalm Therapeutics was spun out of a parent defense contractor and drug discovery company, CFD Research, and continues to co-locate on their campus and utilize their lab space.

Funds Raised: \$350K in SBIR grants. \$500K in friends and family. Potential \$500K in state accelerator funds.

Presenter: Chris Seibert, MBA, CEO

Lyric Bio, Inc.

(TechBio)

Categorical Listings: Antibodies, Biomanufacturing, Immunology

Location: Oakland, California United States

Year Established: 2024 **Website:** www.lyricbio.com

Corporate Partners: Lyric Bio is a Seed stage company in early discussions with corporate venture groups.

Funds Raised: The company is actively raising its first round.

Presenter: Melanie Matheu, PhD, CSO

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

MedGene Therapeutics, Inc.

Categorical Listings: Cell Therapy, Gene Therapy, Oncology

Location: Gaithersburg, Maryland United States

Year Established: 2021 **Website:** www.medgenetx.com

Corporate Partners: None

Funds Raised: INP

Presenter: Yong Park, MD, CEO

Merlin Biotech, Inc.

Categorical Listings: Immuno-oncology, Oncology, Platform Technology

Location: Doylestown, Pennsylvania United States

Year Established: 2022 **Website:** www.merlinbiotech.com

Corporate Partners: None

Funds Raised: Over \$1M in non-dilutive and dilutive notes.

Presenter: Randall Hyer, MD, PhD, MPH, CEO

Museum of Medicine and Biomedical Discovery

Categorical Listings: Drug Discovery, Longevity/Healthspan/Diseases of Aging, Personalized Medicine

Location: Nashville, Tennessee United States

Year Established: 2022 **Website:** www.mmbd.org

Corporate Partners: None. Credibility will be based on being independent of big pharma. Seeking support from individuals, organizations, and foundations that recognize the value of this museum.

Funds Raised: \$200K. Seeking \$15+M.

Presenter: Mace Rothenberg, MD, President & Executive Director

TOC

BF
profilesBF
CategoricalSEED
profilesSEED
Categorical

Myracle Therapeutics, Inc.

Categorical Listings: Drug Discovery, Endocrine-Metabolic, Longevity/Healthspan/Diseases of Aging

Location: East Hanover, New Jersey United States

Year Established: 2023 **Website:** www.myracletx.com

Corporate Partners: None

Funds Raised: \$2.3M in non-dilutive capital (SBIR Fast Track)

Presenter: Dawn Bell, PharmD, Executive Chair

Myria Biosciences AG

Categorical Listings: Artificial Intelligence (AI), Drug Discovery, Platform Technology

Location: Basel, Switzerland

Year Established: 2022 **Website:** www.myria.bio

Corporate Partners: In a partnership with a Top10 Pharma company for an undisclosed indication.

Funds Raised: INP

Presenter: Irene Wuethrich, MS, COO

New England Hemolytics Inc.

Categorical Listings: Diagnostics, Hematology, Infectious Disease

Location: Branford, Connecticut United States

Year Established: 2021 **Website:** newenglandhemolytics.com

Corporate Partners: Partnering with a leading multiplex PCR kit provider for a complete diagnostic solution.

Funds Raised: Less than \$500K, from founders and NSF SBIR Phase 1 grant.

Presenter: John Nobile, CEO & Founder



Nostopharma

Categorical Listings: Drug Delivery, Longevity/Healthspan/Diseases of Aging, Musculoskeletal

Location: Bethesda, Maryland United States

Year Established: 2021 **Website:** www.nostopharma.com

Corporate Partners: Nostopharma is part of Johnson & Johnson Innovation network as an incubator company at Washington DC JLABS.

Funds Raised: Nostopharma has received non-dilutive funding (most recently, Phase 2 grant from NSF) and is initiating Seed round.

Presenter: Ekaterina Vert-Wong, CEO

Octozi

Categorical Listings: Artificial Intelligence (AI), Big Data, Machine Learning

Location: New York, New York, United States

Year Established: 2023 **Website:** www.octozi.com

Corporate Partners: INP

Funds Raised: \$200K

Presenter: Amit Patel, CEO

OncoRx Insights, Inc.

(TechBio)

Categorical Listings: Machine Learning, Natural language processing (NLP)/Large language models (LLM), Oncology

Location: Boulder, Colorado United States

Year Established: 2022 **Website:** www.oncorxinsights.com

Corporate Partners: The company has a Master Data Agreement with a large West Coast cancer center, and is seeking early adopter pharma partners for codevelopment of its pharma data offerings.

Funds Raised: Founder funded with \$250K provided to date. Seeking a Seed round of \$2.5M to \$4M.

Presenter: Dave Parkhill, MS, CEO & Co-Founder



Oqory, Inc.

(TechBio)

Categorical Listings: Antibodies, Oncology, Oncology Combination Therapy

Location: San Diego, California, United States

Year Established: 2024 **Website:** INP

Corporate Partners: None currently

Funds Raised: No capital raised as yet.

Presenter: Michael (Mike) G King, CEO

Paint Therapeutics

Categorical Listings: Drug Delivery, Oncology, Pulmonary

Location: Atlanta, Georgia, United States

Year Established: 2022 **Website:** painttherapeutics.com

Corporate Partners: Seed funded

Funds Raised: \$800K

Presenter: Bill Reddick, MHA, CEO

ReSync Bio, Inc.

(TechBio)

Categorical Listings: Contract Drug Development, Drug Discovery, Machine Learning

Location: San Francisco, California United States

Year Established: 2024 **Website:** resync.bio

Corporate Partners: The company is working with multiple biotechs, including a Series B company with over \$100M in funding.

Funds Raised: INP

Presenter: Mihir Trivedi, MS, CEO



TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

Seed Showcase Categorical Listings

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

TOC

BF
profiles

BF
Categorical

SEED
profiles

SEED
Categorical

Antibodies

Lyric Bio, Inc.
 Oqory, Inc.

Artificial Intelligence (AI)

BioCurie
 Myria Biosciences AG
 Octozi

Big Data

Octozi

Biomanufacturing

BioCurie
 Lyric Bio, Inc.

Cell Therapy

CARLA Biotherapeutics
 MedGene Therapeutics, Inc.

CNS-Neurological

Invenis Biotherapies

Contract Drug Development

ReSync Bio, Inc.

Dermatology

Kalm Therapeutics

Diagnostics

New England Hemolytics Inc.



Drug Delivery

ImBiome Inc.
Nostopharma
Paint Therapeutics

Drug Discovery

Museum of Medicine and Biomedical Discovery
Myracle Therapeutics, Inc.
Myria Biosciences AG
ReSync Bio, Inc.

Endocrine-Metabolic

Myracle Therapeutics, Inc.

Gene Therapy

BioCurie
MedGene Therapeutics, Inc.

Hematology

New England Hemolytics Inc.

Immunology

Kalm Therapeutics
Lyric Bio, Inc.

Immuno-oncology

Merlin Biotech, Inc.

Infectious Disease

New England Hemolytics Inc.

TOC

BF
profilesBF
CategoricalSEED
profilesSEED
Categorical

Longevity/Healthspan/Diseases of Aging

Museum of Medicine and Biomedical Discovery
 Myracle Therapeutics, Inc.
 Nostopharma

Machine Learning

Octozi
 OncoRx Insights, Inc.
 ReSync Bio, Inc.

Microbiome

ImBiome Inc.
 Kalm Therapeutics

Musculoskeletal

Nostopharma

Natural language processing (NLP)/Large language models (LLM)

OncoRx Insights, Inc.

Oncology

CARLA Biotherapeutics
 MedGene Therapeutics, Inc.
 Merlin Biotech, Inc.
 OncoRx Insights, Inc.
 Oqory, Inc.
 Paint Therapeutics

Oncology Combination Therapy

Oqory, Inc.



Orphan-Rare Disease

Invenis Biotherapies

Other

Kaida BioPharma

Personalized Medicine

CARLA Biotherapeutics

Museum of Medicine and Biomedical Discovery

Platform Technology

ImBiome Inc.

Merlin Biotech, Inc.

Myria Biosciences AG

Pulmonary

Paint Therapeutics

Regenerative Medicine


Invenis Biotherapies

TOC

BF
profilesBF
CategoricalSEED
profilesSEED
Categorical



Reimagine the future of healthcare



See you next year!

October 2025 • New York City

Challenge current wisdom.

Debate new trends.

Discover new frontiers.

Produced by
 **DEMY
COLTON**

 **DEMY COLTON**

demy-colton.com